Clinical characteristics and survival of patients with IgD multiple myeloma.
作者信息
Li Yi, Cai Zhen
机构信息
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
Institute of Hematology, Zhejiang University, Zhejiang, Hangzhou, China.
出版信息
Blood Sci. 2021 Apr 27;3(2):57-58. doi: 10.1097/BS9.0000000000000066. eCollection 2021 Apr.
Abstract
摘要
相似文献
1
Clinical characteristics and survival of patients with IgD multiple myeloma.IgD型多发性骨髓瘤患者的临床特征与生存情况
Blood Sci. 2021 Apr 27;3(2):57-58. doi: 10.1097/BS9.0000000000000066. eCollection 2021 Apr.
2
Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.新型药物时代免疫球蛋白 D 型骨髓瘤的临床特征和预后。
Ann Hematol. 2019 Apr;98(4):963-970. doi: 10.1007/s00277-018-3582-4. Epub 2019 Jan 4.
3
N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.血清蛋白的 N-糖基化用于评估 IgD 多发性骨髓瘤患者。
BMC Cancer. 2017 Dec 21;17(1):881. doi: 10.1186/s12885-017-3891-3.
4
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.免疫球蛋白D型骨髓瘤：新型药物时代的临床特征与预后
Eur J Haematol. 2014 Apr;92(4):308-12. doi: 10.1111/ejh.12255. Epub 2014 Jan 26.
5
Is IgD Myeloma a Separate Clinical Entity? Report of Six Cases Investigated by Isoelectric Focusing.
Leuk Lymphoma. 1990;2(6):385-90. doi: 10.3109/10428199009069291.
6
IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.IgD型多发性骨髓瘤：血清游离轻链检测的临床、生物学特征及预后价值
Pathol Biol (Paris). 2015 Sep;63(4-5):210-4. doi: 10.1016/j.patbio.2015.06.002. Epub 2015 Aug 17.
7
[Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Apr;29(2):547-552. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.038.
8
IgD multiple myeloma with renal involvement: case report.IgD型多发性骨髓瘤伴肾脏受累：病例报告
Jpn J Med. 1990 Mar-Apr;29(2):212-5. doi: 10.2169/internalmedicine1962.29.212.
9
Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review).免疫球蛋白D型骨髓瘤——诊断与分期问题（个人经验及文献综述）
Leuk Lymphoma. 2005 Jul;46(7):1029-37. doi: 10.1080/00268970500096442.
10
Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.异基因移植治疗IgD型和非分泌型骨髓瘤的疗效及结果。欧洲血液和骨髓移植组慢性恶性肿瘤工作组骨髓瘤小组委员会的报告
Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.
引用本文的文献
1
Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders.罕见病种，罕见挑战：罕见浆细胞疾病综述
Hematol Rep. 2025 Jun 27;17(4):31. doi: 10.3390/hematolrep17040031.
2
Diagnostic d'un myélome multiple à immunoglobuline D Lambda avec une atteinte rénale sévère 10 ans après un plasmocytome solitaire : Un cas clinique et revue de la littérature.孤立性浆细胞瘤10年后诊断为伴有严重肾脏受累的IgD λ型多发性骨髓瘤：1例临床病例及文献复习
Tunis Med. 2025 Jan 5;103(1):158-161. doi: 10.62438/tunismed.v103i1.5253.
3
Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma.联合人工智能驱动的新诊断和复发多发性骨髓瘤事件预测与纵向建模
NPJ Digit Med. 2024 Jul 29;7(1):200. doi: 10.1038/s41746-024-01189-3.
本文引用的文献
1
Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).IgD 型骨髓瘤的临床特征与生存结局：亚洲骨髓瘤网络（AMN）的一项研究
Leukemia. 2021 Jun;35(6):1797-1802. doi: 10.1038/s41375-020-01060-w. Epub 2020 Oct 20.
2
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.新型药物时代免疫球蛋白D型多发性骨髓瘤患者的不良预后：单中心经验
Cancer Commun (Lond). 2019 Sep 27;39(1):51. doi: 10.1186/s40880-019-0395-3.
3
Presentation Patterns, Diagnostic Markers, Management Strategies, and Outcomes of IgD Multiple Myeloma: A Systematic Review of Literature.IgD型多发性骨髓瘤的临床表现模式、诊断标志物、管理策略及预后：文献系统综述
Cureus. 2019 Feb 4;11(2):e4011. doi: 10.7759/cureus.4011.
4
Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.新型药物时代免疫球蛋白 D 型骨髓瘤的临床特征和预后。
Ann Hematol. 2019 Apr;98(4):963-970. doi: 10.1007/s00277-018-3582-4. Epub 2019 Jan 4.
5
Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma.使用流式细胞术检测细胞内 IgD 可能是诊断 IgD 多发性骨髓瘤的一种新颖且补充的方法。
BMC Cancer. 2018 Jun 11;18(1):650. doi: 10.1186/s12885-018-4562-8.
6
Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.韩国免疫球蛋白D型多发性骨髓瘤病例中使用新型药物和自体干细胞移植的疗效及生存结果
Acta Haematol. 2018;139(3):185-192. doi: 10.1159/000486664. Epub 2018 Apr 10.
7
N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.血清蛋白的 N-糖基化用于评估 IgD 多发性骨髓瘤患者。
BMC Cancer. 2017 Dec 21;17(1):881. doi: 10.1186/s12885-017-3891-3.
8
[Clinical characteristics analyses of 27 cases of immunoglobin D multiple myeloma].27例免疫球蛋白D型多发性骨髓瘤临床特征分析
Zhonghua Xue Ye Xue Za Zhi. 2017 Oct 14;38(10):893-895. doi: 10.3760/cma.j.issn.0253-2727.2017.10.014.
9
More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.中国50岁以下多发性骨髓瘤患者中IgD更频繁且CD200表达降低：一项多中心分析。
Drug Des Devel Ther. 2016 Nov 8;10:3673-3679. doi: 10.2147/DDDT.S100062. eCollection 2016.
10
Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival.免疫球蛋白D型多发性骨髓瘤：疾病概况、治疗反应及生存情况
Acta Haematol. 2016;136(3):140-6. doi: 10.1159/000446599. Epub 2016 Jul 14.
Zotero 插件